electroCore, Inc. (ECOR)
NCM · Healthcare · Medical Devices
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
About electroCore, Inc.
electroCore, Inc., a bioelectronic technology medicine and general wellness company, provides non-invasive vagus nerve stimulation (nVNS) technology platform in the United States, the United Kingdom, and internationally. The company develops gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga 350, a personal use consumer electronics general wellness product and Truvaga Plus, an app-enabled general wellness product. It also offers non-invasive bioelectronic therapies for the treatment of chronic pain and wellness conditions. In addition, the company offers TAC-STIM for human performance and gammaCore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 7.4M | 8.7M | 9.2M | 9.6M |
| Gross Profit | 6.4M | 7.5M | 8.2M | 8.4M |
| Operating Income | -3.5M | -2.9M | -2.9M | -5.3M |
| Net Income | -3.7M | -3.4M | -3.0M | -5.3M |
| Diluted EPS | $-0.44 | $-0.40 | $nan | $-0.59 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 8.6M | 16.0M | 25.2M | 32.0M |
| Gross Profit | 7.0M | 13.2M | 21.4M | 27.8M |
| Operating Income | -22.9M | -19.3M | -12.2M | -13.2M |
| Net Income | -22.2M | -18.8M | -11.9M | -14.0M |
| Diluted EPS | $-4.69 | $-3.42 | $-1.59 | $-1.65 |